Fumagillin
QP51AX23 (WHO ) | |
Identifiers | |
---|---|
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Fumagillin is a complex biomolecule and used as an antimicrobial agent. It was isolated in 1949 from the microbial organism Aspergillus fumigatus.[1]
Uses
In animals
It was originally used against microsporidian parasites Nosema apis infections in honey bees.[citation needed]
Some studies found it to be effective against some
There are reports that fumagillin controls Nosema ceranae,[2] which has recently been hypothesized as a possible cause of colony collapse disorder.[3][4] The latest report, however, has shown it to be ineffective against N. ceranae.[5] Fumagillin is also investigated as an inhibitor of malaria parasite growth.[6][7]
In humans
Fumagillin has been used in the treatment of microsporidiosis.[8][9] It is also an amebicide.[10]
Fumagillin can block blood vessel formation by binding to an enzyme methionine aminopeptidase 2[11] and for this reason, the compound, together with semisynthetic derivatives, are investigated as an angiogenesis inhibitor[12] in the treatment of cancer.
The company Zafgen conducted clinical trials using the fumagillin
Fumagillin is toxic to
Total synthesis
Fumagillin and the related fumagillol (the hydrolysis product) have been a target in total synthesis, with several reported successful strategies, racemic, asymmetric, and formal.[16][17][18][19][20][21][22][23][24]
References
- ^ F. R. Hanson, T. E. Elbe, J. Bacteriol. 1949, 58, 527
- PMID 18550078.
- ^ Sabin Russell (2007-04-26). "UCSF scientist tracks down suspect in honeybee deaths". San Francisco Chronicle.
- ^ "Scientists Identify Pathogens That May Be Causing Global Honeybee Deaths" (PDF). Edgewood Chemical Biological Center. 2007-04-25.[verification needed]
- PMID 23505365.
- PMID 19246010.
- PMID 19648008.
- S2CID 205423324.
- PMID 12075057.
- S2CID 41794515.
- ^
Gilbert MA, Granath WO (August 2003). "Whirling disease of salmonid fish: life cycle, biology, and disease". The Journal of Parasitology. 89 (4): 658–667. S2CID 8950955.
- S2CID 1020594.
- ^ "Zafgen Announces Positive Topline Phase 1b Data for ZGN-433 in Obesity". MedNews. Drugs.com. 5 January 2011.
- ^ "Zafgen Halts Development of Beloranib, to Cut Jobs by ~34%". nasdaq.com. July 20, 2016.
- PMID 23121865.
- PMID 5016935.
- .
- PMID 29711854.
- S2CID 196782462.
- S2CID 95897985.
- PMID 11506622.
- .
- PMID 16365904.
- PMID 20209516.